5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine | 506407-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine
• 英文别名: 2-amino-5-(4-tert-butylphenyl)-1,3,4-oxadiazole；2-amino-5-(4-tert-butylphenyl)[1,3,4]oxadiazole；5-(4-tert-Butylphenyl)-[1,3,4]oxadiazol-2-ylamine；5-(4-Tert-butylphenyl)-1,3,4-oxadiazol-2-amine
• CAS: 506407-84-7
• 化学式: C₁₂H₁₅N₃O
• mdl: MFCD00099616
• 分子量: 217.271
• InChiKey: OISTTWCWVFSFNE-UHFFFAOYSA-N

物化性质

• 溶解度：
  1.5 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine 在 溶剂黄146 、 过碘酸 作用下， 生成 Bis-[5-(4-tert-butyl-phenyl)-[1,3,4]oxadiazol-2-yl]-diazene
  参考文献：
  名称：

  Pradhan, Banasova; Misro; Padhy, Arun Kumar, Journal of the Indian Chemical Society, 2002, vol. 79, # 11, p. 898 - 900

  摘要：

  DOI：
• 作为产物：
  描述：

  4-tert-butylbenzaldehyde semicarbazone 在 四溴化碳 、 溶剂红 43 作用下， 以 乙腈 为溶剂， 以86%的产率得到5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine
  参考文献：
  名称：

  Photocatalytic Oxidative Heterocyclization of Semicarbazones: An Efficient Approach for the Synthesis of 1,3,4-Oxadiazoles

  摘要：

  A highly efficient eosin Y catalyzed oxidative heterocyclization of semicarbazones was established under visible-light photoredox catalysis using CBr4 as a bromine source. The protocol renders a rapid, mild, and efficient access to valuable 5-substituted 2-amino-1,3,4-oxadiazoles in an operationally simple way utilizing visible light and atmospheric oxygen.

  DOI：

  10.1055/s-0034-1380493

文献信息

• SMALL MOLECULE MODULATORS OF CELL ADHESION
  申请人：Gupta Mukur

  公开号：US20090291967A1

  公开（公告）日：2009-11-26

  Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, X, Y, Z, m and n are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed.

  化合物，特别是具有作为调节cadherin介导的细胞粘附活性的化合物，具有以下结构：或其药用盐、立体异构体或前药，其中R1、R2、R3、R4、R5、R6、A、X、Y、Z、m和n如本文所定义。与其制备和使用相关的方法，以及含有该化合物的药物组合物也被披露。
• N,N-Dialkyl-N´-Chlorosulfonylchloroformamidines in Heterocyclic Synthesis. II. Thiazolo-, Thiadiazolo-, and Oxadiazolo-Fused [1,2,4,6]Thiatriazine Dioxides
  作者：Gary D. Fallon、Craig L. Francis、Katarina Johansson、Andris J. Liepa、Ruth C. J. Woodgate

  DOI：10.1071/ch05070

  日期：——

  N,N-dialkyl-N′-chlorosulfonylchloroformamidines 1 were treated with 2-aminothiazoline, 2-aminothiazoles, 2-aminobenzothiazoles, 2-amino-1,3,4-thiadiazoles, and 2-amino-1,3,4-oxadiazoles to give a 6,7-dihydrothiazolo[3,2-b][1,2,4,6]thiatriazine dioxide 3, a 6,7-dihydrothiazolo[2,3-c][1,2,4,6]thiatriazine dioxide 4, thiazolo[3,2-b][1,2,4,6]thiatriazine dioxides 5, [1,2,4,6]thiatriazino[3,2-b]benzothiazole dioxides 7, a [1,2,4,6]thiatriazino[3,4-b]benzothiazole dioxide 8, [1,3,4]thiadiazolo[2,3-c][1,2,4,6]thiatriazine dioxides 10, [1,3,4]thiadiazolo[3,2-b][1,2,4,6]thiatriazine dioxides 11, [1,3,4]oxadiazolo[2,3-c][1,2,4,6]thiatriazine dioxides 13, and [1,3,4]thiadiazolo[3,2-b][1,2,4,6]thiatriazine dioxides 14. Compounds 3, 4, 5, 7, 8, 10, 11, 13, and 14 are derivatives of new ring systems.

  将 N,N-二烷基-N′-氯磺酰基氯甲酰胺 1 与 2-氨基噻唑啉、2-氨基噻唑、2-氨基苯并噻唑、2-氨基-1,3,4-噻二唑和 2-氨基-1,3、4-噁二唑，从而得到 6,7- 二氢噻唑并[3,2-b][1,2,4,6]噻嗪二氧化物 3、6,7- 二氢噻唑并[2,3-c][1,2,4,6]噻嗪二氧化物 4、噻唑并[3,2-b][1,2,4,6]噻嗪二氧化物 5、[1,2,4,6]噻三嗪并[3,2-b]苯并噻唑二氧化物 7、[1,2,4,6]噻三嗪并[3,4-b]苯并噻唑二氧化物 8、[1,3,4]噻二唑并[2,3-c][1,2,4,6]噻嗪二氧化物 10、[1,3、4]噻二唑并[3,2-b][1,2,4,6]噻三嗪二恶英 11、[1,3,4]噁二唑并[2,3-c][1,2,4,6]噻三嗪二恶英 13 和 [1,3,4]噻二唑并[3,2-b][1,2,4,6]噻三嗪二恶英 14。化合物 3、4、5、7、8、10、11、13 和 14 是新环系的衍生物。
• A Convenient Synthesis of 5-substituted 2-amino-1,3,4-oxadiazoles from Corresponding Acylthiosemicarbazides Using iodine and Oxone®
  作者：Vikas N. Shinde、Bheemarao G. Ugarkar、Sandeep R. Ghorpade

  DOI：10.3184/174751912x13551638283701

  日期：2013.1

  A convenient methodology has been developed for the synthesis of substituted 2-amino-1,3,4-oxadiazoles from corresponding acylthiosemicarbazides using catalytic amount of iodine/KI in the presence of Oxone® as a bulk oxidant. This offers the advantage of short reaction times and substrate variability which is suitable for the rapid production of analogues required for lead optimisation programmes. The method could also be useful for large-scale synthesis because of the mild reaction conditions and the use commercially inexpensive and safe reagents.

  我们开发了一种简便的方法，在 Oxone® 作为大量氧化剂存在的情况下，使用催化量的碘/KI，从相应的酰基硫代氨基甲酰肼合成取代的 2-氨基-1,3,4-恶二唑。这种方法具有反应时间短、底物可变性强的优点，适合快速生产先导优化计划所需的类似物。由于反应条件温和，且使用的试剂在商业上既便宜又安全，因此该方法也可用于大规模合成。
• Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents
  作者：Apeng Wang、Shijie Xu、Yun Chai、Guimin Xia、Bin Wang、Kai Lv、Dan Wang、Xiaoyu Qin、Bin Jiang、Wenhao Wu、Mingliang Liu、Yu Lu

  DOI：10.1016/j.bmc.2021.116529

  日期：2022.1

  Three series of novel nitrofuran-1,3,4-oxadiazole hybrids were designed and synthesized as new anti-TB agents. The structure activity relationship study indicated that the linkers and the substituents on the oxadiazole moiety greatly influence the activity, and the substituted benzenes are more favoured than the cycloalkyl or heterocyclic groups. Besides, the optimal compound in series 2 was active

  设计并合成了三个系列的新型硝基呋喃-1,3,4-恶二唑杂化物作为新型抗结核药物。构效关系研究表明，恶二唑部分的连接基和取代基对活性影响很大，取代的苯比环烷基或杂环基更受青睐。此外，系列 2 中的最佳化合物对 MTB H 37 Rv 菌株和 MDR-MTB 16883 临床分离株均具有活性，并且还显示出低细胞毒性、低 hERG 抑制和良好的口服 PK，表明其有望成为进一步结构的领先者。修改。
• Treatment of proliferative diseases
  申请人：Dennis Jim

  公开号：US20070244071A1

  公开（公告）日：2007-10-18

  The invention relates generally to compositions comprising malonate compounds, and methods and uses of the compositions in the treatment of proliferative diseases. In particular the invention relates to a pharmaceutical composition comprising a compound of the formula I wherein * is ═C or ═O, R1 and R2 independently represent substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, carboxamide, carboxylic ester, phosphono, a substituted or unsubstituted aryl group fused to a cycloalkyl group, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, excipients, and vehicles.